Copy of Annual Report 2024 - Report - Page 7
Research
Research plays a pivotal role at A Cure In Sight (ACIS). Since the inception of our
research program, ACIS has allocated funding to projects that might have otherwise
been halted and left unfinished. Each medical research grant is carefully reviewed
by our research committee, along with Cancer Navigator Hartmut Stecher, PhD, MS.
Funding is contingent upon adhering to strict contractual terms. Additionally, ACIS
collaborates with the Melanoma Research Alliance to offer an annual grant funded
through our Steps For Sight Campaign.
In 2024, ACIS dedicated $133,570 to research initiatives aimed at enhancing
understanding in the treatment of ocular melanoma. Our focus is on clinical
research that can be implemented swiftly to benefit patients.
Insight Registry
The A Cure In Sight Insight Registry offers a remarkable
chance for patients with Ocular Melanoma to actively
engage in research. It stands as the largest registry for
patient input in Ocular Melanoma, currently boasting 1,068
enrolled respondents and 854 active participants. In 2024,
the registry platform underwent enhancements to provide a
more user-friendly experience.
This Insight Registry is a collaborative initiative between
ACIS and Dr. Armin Afshar of UCSF, and it will celebrate its
fifth anniversary in July 2025. Applications for data will be
welcomed for use by researchers and physicians.
In 2025, ACIS plans to introduce a biobank associated with
the Insight Registry. Collaborating with Pattern.org and Dr.
Justin Moser, the collection of biopsied metastatic tumor
cells and primary eye tumors will commence. These cells will
be connected to the patient profiles linked to the biopsies,
offering groundbreaking context for research on these cells.
This will mark the establishment of the first independent
biobank in the realm of Ocular Melanoma research.
854
enrolled
respondents
7301
Completed
Surveys
